David Kelly Net Worth

The estimated Net Worth of David George Kelly is at least $39.1 mil dollars as of 13 June 2020. Mr. Kelly owns over 11,406 units of Iterum Therapeutics Plc stock worth over $39,149 and over the last 10 years he sold ITRM stock worth over $0. In addition, he makes $0 as Independent Director at Iterum Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kelly ITRM stock SEC Form 4 insiders trading

David has made over 2 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 11,406 units of ITRM stock worth $12,033 on 13 June 2020.

The largest trade he's ever made was exercising 11,406 units of Iterum Therapeutics Plc stock on 13 June 2020 worth over $12,033. On average, David trades about 1,784 units every 47 days since 2015. As of 13 June 2020 he still owns at least 37,108 units of Iterum Therapeutics Plc stock.

You can see the complete history of Mr. Kelly stock trades at the bottom of the page.

David Kelly biography

David G. Kelly serves as Independent Director of the Company. From September 2014 to January 2020, Mr. Kelly served as the executive vice president, Ireland of Horizon Therapeutics, plc, a biopharmaceutical company. Mr. Kelly served as managing director, Ireland of Horizon Therapeutics, plc until July 2018. From February 2012 to September 2014, Mr. Kelly served as chief financial officer of Vidara Therapeutics Inc., a pharmaceutical company. From May 2005 to January 2012, Mr. Kelly served as chief financial officer of AGI Therapeutics plc, a pharmaceutical company. Mr. Kelly also served as senior vice president, finance and planning of Warner Chilcott plc (formerly Galen Holdings plc), a pharmaceutical company listed on the London Stock Exchange (LSE). In addition, Mr. Kelly held roles at Elan Corporation, a pharmaceutical company, and KPMG. Mr. Kelly holds a B.A. in economics from Trinity College, Dublin and is also a member of the Institute of Chartered Accountants in Ireland (ACA).

How old is David Kelly?

David Kelly is 59, he's been the Independent Director of Iterum Therapeutics Plc since 2016. There are 2 older and 10 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.

What's David Kelly's mailing address?

David's mailing address filed with the SEC is C/O ITERUM THERAPEUTICS PLC,, FITZWILLIAM COURT, FL. 1, LEESON CLOSE, DUBLIN 2, L2, .

Insiders trading at Iterum Therapeutics Plc

Over the last 7 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital... y James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.

What does Iterum Therapeutics Plc do?

iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.

Complete history of Mr. Kelly stock trades at Horizon Therapeutics Plc y Iterum Therapeutics Plc

Iterum Therapeutics Plc executives and stock owners

Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:

• Corey Fishman,
  Chief Executive Officer, Director
• Corey N. Fishman,
  Pres, CEO & Director
• Michael Dunne,
  Chief Scientific Officer
• Judith Matthews,
  Chief Financial Officer
• Judith M. Matthews,
  Chief Financial Officer
• Dr. Michael W. Dunne M.D.,
  Strategic Advisor & Director
• Dr. Sailaja Puttagunta M.D.,
  Chief Medical Officer
• Brenton Ahrens,
  Independent Interim Chairman of the board
• Shahzad Malik,
  Independent Director
• David Kelly,
  Independent Director
• Ronald Hunt,
  Independent Director
• Patrick Heron,
  Independent Director
• Mark Chin,
  Independent Director
• Dr. Steven I. Aronin M.D.,
  Sr. VP & Head of Clinical Devel.
• Louise Barrett,
  Sr. VP of Legal Affairs & Sec.
• Tom Loughman Ph.D.,
  Sr. VP of Technical Operations
• Beth Hecht,
  Director
• Vijay K Ratcliffe Liam Lathi,
  
• Venture Partners Ix, L.P.Po...,
  
• James Healy,
  Director
• X L.P.Canaan Partners X Llc...,
  
• Paul R Edick,
  Director
• Jeffrey R. Schaffnit,
  Chief Commercial Officer
• Patrick J Heron,
  Director
• Capital Management, L.P.Ra ...,
  
• Healthcare Vii, L.P.Frazier...,
  
• Venture Partners Ix, L.P.So...,
  
• Venture Partners Ix, L.P.So...,
  
• Alexander J Sarissa Capital...,
  
• Sailaja Puttagunta,
  Chief Medical Officer